中国新药杂志

嵌合抗原受体T细胞产品最新研发进展

PDF下载

刘千勇 , Mark GILBERT , 李怡平

中国新药杂志 | 生物医药前沿 2021,30(19): 1759-1767

收起

中国新药杂志 |生物医药前沿 2021 , 30 (19) : 1759 -1767

嵌合抗原受体T细胞产品最新研发进展

全屏

[Author(id=1322906824990655350, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906824168571759, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=charles.Liu@jwtherapeutics.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322906825057764216, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906824168571759, authorId=1322906824990655350, language=EN, stringName=Qian-yong LIU, firstName=Qian-yong, middleName=null, lastName=LIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=JW Therapeutics (Shanghai) Co., Ltd., Shanghai 201210, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322906825124873081, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906824168571759, authorId=1322906824990655350, language=CN, stringName=刘千勇, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=上海药明巨诺生物医药科技有限公司，上海　201210, bio={"content":"

刘千勇，男，博士，研究方向：转化医学和免疫治疗。E-mail：charles.Liu@jwtherapeutics.com。

"}, bioImg=null, bioContent=

刘千勇，男，博士，研究方向：转化医学和免疫治疗。E-mail：charles.Liu@jwtherapeutics.com。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322906824906769266, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906824168571759, xref=null, ext=[AuthorCompanyExt(id=1322906824919352179, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906824168571759, companyId=1322906824906769266, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=JW Therapeutics (Shanghai) Co., Ltd., Shanghai 201210, China), AuthorCompanyExt(id=1322906824931935092, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906824168571759, companyId=1322906824906769266, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海药明巨诺生物医药科技有限公司，上海　201210)])]), Author(id=1322906825225536379, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906824168571759, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322906825309422461, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906824168571759, authorId=1322906825225536379, language=EN, stringName=Mark GILBERT, firstName=Mark, middleName=null, lastName=GILBERT, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=JW Therapeutics (Shanghai) Co., Ltd., Shanghai 201210, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322906825380725631, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906824168571759, authorId=1322906825225536379, language=CN, stringName=Mark GILBERT, firstName=Mark, middleName=null, lastName=GILBERT, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=上海药明巨诺生物医药科技有限公司，上海　201210, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322906824906769266, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906824168571759, xref=null, ext=[AuthorCompanyExt(id=1322906824919352179, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906824168571759, companyId=1322906824906769266, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=JW Therapeutics (Shanghai) Co., Ltd., Shanghai 201210, China), AuthorCompanyExt(id=1322906824931935092, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906824168571759, companyId=1322906824906769266, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海药明巨诺生物医药科技有限公司，上海　201210)])]), Author(id=1322906825594635138, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906824168571759, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=James.Li@jwtherapeutics.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1322906825674326917, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906824168571759, authorId=1322906825594635138, language=EN, stringName=Yi-ping LI, firstName=Yi-ping, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=JW Therapeutics (Shanghai) Co., Ltd., Shanghai 201210, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322906825758212998, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906824168571759, authorId=1322906825594635138, language=CN, stringName=李怡平, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=上海药明巨诺生物医药科技有限公司，上海　201210, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322906824906769266, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906824168571759, xref=null, ext=[AuthorCompanyExt(id=1322906824919352179, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906824168571759, companyId=1322906824906769266, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=JW Therapeutics (Shanghai) Co., Ltd., Shanghai 201210, China), AuthorCompanyExt(id=1322906824931935092, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906824168571759, companyId=1322906824906769266, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海药明巨诺生物医药科技有限公司，上海　201210)])])]

刘千勇, Mark GILBERT, 李怡平

作者信息

上海药明巨诺生物医药科技有限公司，上海　201210

通讯作者:

李怡平，男，MD，研究方向：临床医学和细胞治疗。E-mail：James.Li@jwtherapeutics.com。

作者简介:

刘千勇，男，博士，研究方向：转化医学和免疫治疗。E-mail：charles.Liu@jwtherapeutics.com。

Recent progress in the research and development of CAR-T products

Qian-yong LIU, Mark GILBERT, Yi-ping LI

Affiliations

JW Therapeutics (Shanghai) Co., Ltd., Shanghai 201210, China

出版时间: 2021-10-15

文章导航

摘要

收起

作为近年来发展最快的免疫治疗手段之一，嵌合抗原受体T（chimeric antigen receptors-T，CAR-T）细胞疗法在血液肿瘤治疗中表现出了良好的疗效和可控的安全性能，但在实体瘤治疗方面还面临着诸多挑战。本文综述了CAR-T细胞疗法上市产品的临床表现及其生命周期管理进展，探讨了热门靶点如CD19，BCMA，HER2和GPC3的最新研发进展和挑战，并从增强CAR-T细胞治疗产品的疗效和持续性及提高产品安全性等角度，探讨了面临的问题和解决方案。

关键词

嵌合抗原受体T细胞产品 / 生命周期管理 / 靶点 / 治疗疗效 / 持续性作用 / 毒副作用

Abstract

收起

As one of the fastest-growing immunotherapies in recent years, CAR-T cell therapy has demonstrated good efficacy and tolerable safety profiles in hematological malignancies, whereas their clinical utility in solid tumors is still limited by poor efficacy and safety profiles. This article starts with a brief introduction of commercial CAR-T products with their clinical performance as the basis of regulatory approval and their ongoing life cycle management, followed by a discussion of most popular targets, such as CD19, BCMA, HER2 and GPC3. Challenges as well as current progress with regards to improving efficacy and durability of response and managing toxicity are also discussed.

Key words

chimeric antigen receptors-T / life cycle management / targets / efficacy / durability of response / toxicity

引用本文

刘千勇, Mark GILBERT, 李怡平. 嵌合抗原受体T细胞产品最新研发进展. 中国新药杂志, 2021 , 30 (19) : 1759 -1767 .

Qian-yong LIU, Mark GILBERT, Yi-ping LI. Recent progress in the research and development of CAR-T products[J]. Chinese Journal of New Drugs, 2021 , 30 (19) : 1759 -1767 .

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

ADAMI A, MAHER J. An overview of CAR T-cell clinical trial activity to 2021[J]. Immunother Adv, 2021, 1(1): ltab004.

[2]

ONCOLOGY TL. CAR T-cell therapy for solid tumours[J]. Lancet Oncol, 2021, 22(7): 893.

[3]

FDA. Package Insert-KYMRIAH[EB/OL]. (2021-06-14). https://www.fda.gov/media/107296/download

[4]

RUELLA M, XU J, BARRETT DM, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell[J]. Nat Med, 2018, 24(10): 1499-1503.

[5]

FDA. Package Insert-YESCARTA[EB/OL]. (2021-05-11). https://www.fda.gov/media/108377/download

[6]

PAPADOULI I, MUELLER-BERGHAUS J, BEUNEU C, et al. EMA review of axicabtagene ciloleucel (yescarta) for the treatment of diffuse large B-cell lymphoma[J]. The Oncol, 2020, 25(10): 894-902.

[7]

复星凯特生物科技有限公司. 奕凯达(阿基仑赛注射液)说明书[EB/OL]. (2021-06-23). https://www.nmpa.gov.cn/directory/web/nmpa/yaowen/ypjgyw/2021062309423187.html.

[8]

FDA. Package Insert-TECARTUS[EB/OL]. (2021-03-18). https://www.fda.gov/media/140409/download.

[9]

FDA. Package Insert-BREYANZI[EB/OL]. (2021-03-14). https://www.fda.gov/media/145711/download.

[10]

MAJZNER RG, RIETBERG SP, SOTILLO E, et al. Tuning the antigen density requirement for CAR T-cell activity[J]. Cancer Discov, 2020, 10(5): 702-723.

[11]

MAJZNER RG, MACKALL CL. Tumor antigen escape from CAR T-cell therapy[J]. Cancer Discov, 2018, 8(10): 1219-1226.

[12]

TURTLE CJ, HANAFI LA, BERGER C, et al. CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients[J]. J Clin Invest, 2016, 126(6): 2123-2138.

[13]

FDA. Package Insert-ABECMA[EB/OL]. (2021-03-14). https://www.fda.gov/media/147055/download.

[14]

上海药明巨诺生物科技有限公司. 瑞基奥仑赛注射液说明书[EB/OL]. (2021-09-03). https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20210903084004127.html?type=pc&m=.

[15]

UPADHAYA S, YU JX, SHAH M, et al. The clinical pipeline for cancer cell therapies[J]. Nat Rev Drug Discov, 2021, 20(7): 503-504.

[16]

MOUGIAKAKOS D, KRÖNKE G, VÖLKL S, et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus[J]. N Engl J Med, 2021, 385(6): 567-569.

[17]

KANSAL R, RICHARDSON N, NEELI I, et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus[J]. Sci Transl Med, 2019, 11(482): eaav1648.

[18]

CHONG EA, MELENHORST J, SVOBODA J, et al. Phase Ⅰ/Ⅱ study of pembrolizumab for progressive diffuse large B cell lymphoma after anti-CD19 directed chimeric antigen receptor modified T cell therapy[J]. Blood, 2017, 130(S1): S4121.

[19]

PARK AK, FONG Y, KIM SI, et al. Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors[J]. Sci Transl Med, 2020, 12(559): eaaz1863.

[20]

MADDURI D, BERDEJA JG, USMANI SZ, et al. CARTITUDE-1: phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in relapsed/refractory multiple myeloma[J]. Blood, 2020, 136(Suppl 1): S22-S25.

[21]

ROEX G, TIMMERS M, WOUTERS K, et al. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma[J]. J Hematol Oncol, 2020, 13(1): 164.

[22]

ALI SA, SHI V, MARIC I, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma[J]. Blood, 2016, 128(13): 1688-1700.

[23]

HAMIEH M, DOBRIN A, CABRIOLU A, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape[J]. Nature, 2019, 568(7750): 112-116.

[24]

LAURENT SA, HOFFMANN FS, KUHN PH, et al. γ-secretase directly sheds the survival receptor BCMA from plasma cells[J]. Nat Commun, 2015, 6: 7333.

[25]

COLONNA L, NAVARRO G, DEVRIES T, et al. Orvacabtagene autoleucel (orva-cel; JCARH125): a fully human BCMA-targeted second-generation CAR T cell product characterized by a predominant central memory phenotype with high in vitro and in vivo proliferative potential and sustained in vivo persistence[J]. Blood, 2020, 136(Suppl 1): S11-S12.

[26]

PONT MJ, HILL T, COLE GO, et al. γ-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma[J]. Blood, 2019, 134(19): 1585-1597.

[27]

GARCIA-GUERRERO E, RODRÍGUEZ-LOBATO LG, DANHOF S, et al. ATRA augments BCMA expression on myeloma cells and enhances recognition by BCMA-CAR T-cells[J]. Blood, 2020, 136: 13-14.

[28]

SZÖOÖŐR Á, TÓTH G, ZSEBIK B, et al. Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies[J]. Cancer Lett, 2020, 484: 1-8.

[29]

VITANZA NA, JOHNSON AJ, WILSON AL, et al. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis[J]. Nat Med, 2021, 27(9): 1544-1552.

[30]

HEGDE M, JOSEPH SK, PASHANKAR F, et al. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma[J]. Nat Commun, 2020, 11(1): 3549.

[31]

MORGAN RA, YANG JC, KITANO M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2[J]. Mol Ther, 2010, 18(4): 843-851.

[32]

AHMED N, BRAWLEY VS, HEGDE M, et al. Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma[J]. J Clin Oncol, 2015, 33(15): 1688-1696.

[33]

CHOE JH, WATCHMAKER PB, SIMIC MS, et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma[J]. Sci Transl Med, 2021, 13(591): eabe7378.

[34]

SHI DH, SHI YP, KASEB AO, et al. Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials[J]. Clin Cancer Res, 2020, 26(15): 3979-3989.

[35]

ZHAO ZW, GUO WY, FANG SJ, et al. An armored GPC3-directed CAR-T for refractory or relapsed hepatocellular carcinoma in China: a phase I trial[J]. J Clin Oncol, 2021, 39(Suppl 15): S4095.

[36]

ADACHI K, KANO Y, NAGAI T, et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor[J]. Nat Biotechnol, 2018, 36(4): 346-351.

[37]

PANG NZ, SHI JX, QIN L, et al. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin[J]. J Hematol Oncol, 2021, 14: 118.

[38]

XU Y, YANG Z, HORAN LH, et al. A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release[J]. Cell Discov, 2018, 4: 62.

[39]

Bloomberg. Eureka therapeutics announces initiation of phase Ⅰ/Ⅱ ARYA-3 clinical trial of GPC₃ targeting ARTEMIS^® T cell therapy in liver cancer[EB/OL]. (2021-07-21). https://www.bloomberg.com/press-releases/2021-07-21/eureka-therapeutics-announces-initiation-of-phase-i-ii-arya-3-clinical-trial-of-gpc3-targeting-artemis-t-cell-therapy-in-liver.

[40]

SADELAIN M, RIVIÉRE I, RIDDELL S. Therapeutic T cell engineering[J]. Nature, 2017, 545(7655): 423-431.

[41]

FRAIETTA JA, LACEY SF, ORLANDO EJ, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia[J]. Nat Med, 2018, 24(5): 563-571.

[42]

LIEBER S, REINARTZ S, RAIFER H, et al. Prognosis of ovarian cancer is associated with effector memory CD8+ T cell accumulation in ascites, CXCL9 levels and activation-triggered signal transduction in T cells[J]. OncoImmunology, 2018, 7(5): e1424672.

[43]

MARTINEZ M, MOON EK. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment[J]. Front Immunol, 2019, 10: 128.

[44]

ZHAO Z, CONDOMINES M, VAN DER STEGEN SJC, et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells[J]. Cancer Cell, 2015, 28(4): 415-428.

[45]

KAWALEKAR OU, O'CONNOR RS, FRAIETTA JA, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells[J]. Immunity, 2016, 44(2): 380-390.

[46]

SALTER AI, IVEY RG, KENNEDY JJ, et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function[J]. Sci Signal, 2018, 11(544): eaat6753.

[47]

CAPPELL KM, KOCHENDERFER JN. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains[J]. Nat Rev Clin Oncol, 2021: 1-13.

[48]

BAILEY SR, MAUS MV. Gene editing for immune cell therapies[J]. Nat Biotechnol, 2019, 37(12): 1425-1434.

[49]

SHAH NN, ZHU FL, SCHNEIDER D, et al. Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma[J]. J Clin Oncol, 2019, 37(Suppl 15): 2510.

[50]

KUHN NF, PURDON TJ, VAN LEEUWEN DG, et al. CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response[J]. Cancer Cell, 2019, 35(3): 473-488.e6.

[51]

LOHMUELLER JJ, HAM JD, KVORJAK M, et al. mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting[J]. OncoImmunology, 2018, 7(1): e1368604.

[52]

LEE YG, MARKS I, SRINIVASARAO M, et al. Use of a single CAR T cell and several bispecific adapters facilitates eradication of multiple antigenically different solid tumors[J]. Cancer Res, 2019, 79(2): 387-396.

[53]

MOON EK, CARPENITO C, SUN J, et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor[J]. Clin Cancer Res, 2011, 17(14): 4719-4730.

[54]

KONERU M, O'CEARBHAILL R, PENDHARKAR S, et al. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer[J]. J Transl Med, 2015, 13: 102.

[55]

TANG L, ZHENG Y, MELO MB, et al. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery[J]. Nat Biotechnol, 2018, 36(8): 707-716.

[56]

ADUSUMILLI PS, ZAUDERER MG, RUSCH VW, et al. Abstract CT036: a phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy[J]. AACR, 2019, 79(Suppl 13): CT036.

[57]

CHERKASSKY L, MORELLO A, VILLENA-VARGAS J, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition[J]. J Clin Invest, 2016, 126(8): 3130-3144.

[58]

RUPP LJ, SCHUMANN K, ROYBAL KT, et al. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells[J]. Sci Rep, 2017, 7(1): 737.

[59]

LE RQ, LI L, YUAN WS, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome[J]. The Oncol, 2018, 23(8): 943-947.

[60]

SI S, TEACHEY DT. Spotlight on tocilizumab in the treatment of CAR-T-cell-induced cytokine release syndrome: clinical evidence to date[J]. Ther Clin Risk Manag, 2020, 16: 705-714.

[61]

LOCKE FL, NEELAPU SS, BARTLETT NL, et al. Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL)[J]. Blood, 2017, 130: 1547.

[62]

NISHIMOTO N, TERAO K, MIMA T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease[J]. Blood, 2008, 112(10): 3959-3964.

[63]

NELLAN A, MCCULLY CML, CRUZ GARCIA R, et al. Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques[J]. Blood, 2018, 132(6): 662-666.

[64]

GUST J, HAY KA, HANAFI LA, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells[J]. Cancer Discov, 2017, 7(12): 1404-1419.

[65]

PALIOGIANNI F, AHUJA SS, BALOW JP, et al. Novel mechanism for inhibition of human T cells by glucocorticoids. Glucocorticoids inhibit signal transduction through IL-2 receptor[J]. J Immunol, 1993, 151(8): 4081-4089.

[66]

LANZA L, SCUDELETTI M, PUPPO F, et al. Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes[J]. Clin Exp Immunol, 2007, 103(3): 482-490.

[67]

BRENTJENS RJ, DAVILA ML, RIVIERE I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia[J]. Sci Transl Med, 2013, 5(177): 177ra38.

[68]

DAVILA ML, RIVIERE I, WANG X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia[J]. Sci Transl Med, 2014, 6(224): 224ra25.

[69]

TOPP M, VAN MEERTEN T, HOUOT R, et al. Earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B cell lymphoma[J]. Blood, 2019, 134(Suppl 1): 243.

[70]

OLUWOLE OO, BOUABDALLAH K, MUÑOZ J, et al. Prophylactic steroid use with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory large B cell lymphoma (R/R LBCL)[J]. Transplant Cell Ther, 2021, 27(3): S68.

[71]

GARDNER RA, CEPPI F, RIVERS J, et al. Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy[J]. Blood, 2019, 134(24): 2149-2158.

[72]

CARUSO HG, HEIMBERGER AB, COOPER LJN. Steering CAR T cells to distinguish friend from foe[J]. OncoImmunology, 2019, 8(10): e1271857.

[73]

SINGH AP, ZHENG XR, LIN-SCHMIDT X, et al. Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model[J]. MAbs, 2020, 12(1): 1688616.

[74]

STERNER RM, SAKEMURA R, COX MJ, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts[J]. Blood, 2019, 133(7): 697-709.

[75]

GIAVRIDIS T, VAN DER STEGEN SJC, EYQUEM J, et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade[J]. Nat Med, 2018, 24(6): 731-738.

[76]

STAEDTKE V, BAI RY, KIM K, et al. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome[J]. Nature, 2018, 564(7735): 273-277.

[77]

GRIFFIOEN M, VAN EGMOND EH, KESTER MG, et al. Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy[J]. Haematologica, 2009, 94(9): 1316-1320.

[78]

DI STASI A, TEY SK, DOTTI G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy[J]. N Engl J Med, 2011, 365(18): 1673-1683.

[79]

MESTERMANN K, GIAVRIDIS T, WEBER J, et al. The tyrosine kinase inhibitor dasatinib Acts as a pharmacologic on/off switch for CAR T cells[J]. Sci Transl Med, 2019, 11(499): eaau5907.

[80]

HACKETHAL V. In remission for 10 years: long-term toxicity data on CAR T cells[EB/OL]. (2020-07-21). https://www.medscape.com/viewarticle/934286.

[81]

RUARK J, MULLANE E, CLEARY N, et al. Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy[J]. Biol Blood Marrow Transplant, 2020, 26(1): 34-43.

[82]

CORDEIRO A, BEZERRA ED, HIRAYAMA AV, et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells[J]. Biol Blood Marrow Transplant, 2020, 26(1): 26-33.

[83]

CAPPELL KM, SHERRY RM, YANG JC, et al. Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy[J]. J Clin Oncol, 2020, 38(32): 3805-3815.

[84]

FDA. Guidance on long term follow-up after administration of human gene therapy products[EB/OL]. (2020-01-30). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/long-term-follow-after-administration-human-gene-therapy-products.

2021年第30卷第19期

PDF下载

引用本文

BibTeX

文章信息

首发时间：2026-10-30
出版时间：2021-10-15

补充材料

相关文章

文章信息

作者

出版历史

录用日期：2021-08-22

基金

作者信息

上海药明巨诺生物医药科技有限公司，上海　201210

通讯作者:

李怡平，男，MD，研究方向：临床医学和细胞治疗。E-mail：James.Li@jwtherapeutics.com。

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1322906824168571759

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT